1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Jasper’s Briquilimab Stands Up To Competition, But Investors Bail

 
• By Jessica Merrill

The company reported positive Phase II data from the BEACON trial testing the c-Kit inhibitor in chronic spontaneous urticaria and said it is planning a Phase IIb/III program.

(Shutterstock)
Key Takeaways

Jasper’s Phase II BEACON trial testing the c-Kit inhibitor briquilimab in chronic spontaneous urticaria was positive.

Investors reacted negatively to the news, however, perhaps due to data inconsistencies across doses and the competitive dynamics in the market.

Novartis and Celldex are further ahead in development with rival drugs, though briquilimab’s efficacy appeared to be on par on with data reported for those drugs.

Jasper Therapeutics’ c-Kit inhibitor, briquilimab, demonstrated efficacy in a Phase II trial in patients with chronic spontaneous urticaria (CSU) that appears on par with rival Celldex’s barzolvolimab. However, the small...

In the Phase Ib/IIa BEACON trial, moderate-to-severe CSU patients treated with various doses of briquilimab experienced substantial reductions in Urticaria Activity Score over 7 days (UAS7), a weekly disease activity...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Merus’ Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

More from Immunological